Novo Nordisk's future in doubt after Wegovy maker's 'surprise' CEO ouster

Published Tue, May 20 20251:23 AM EDTUpdated Tue, May 20 20251:52 AM EDT

Karen Gilchrist @karengilchrist1 @_karengilchrist

Key Points

Novo Nordisk's ousting of its longtime CEO has bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
"[It's] a gigantic surprise," analysts at Denmark's Sydbank wrote in a note shortly after the announcement.
Deutsche Bank said it had "mixed feelings," commending Novo for taking ownership for recent shortcomings, but also questioning the timing of the decision.

Novo Nordisk 's ousting of longtime CEO Lars Fruergaard Jørgensen shocked analysts, with many questioning the future of the Wegovy obesity drug maker in its quest to fend off competition. The Danish pharmaceutical giant on Friday said that its chief was stepping down over concerns that the company was losing its market lead, adding that he would remain in situ throughout the search for a replacement. "[It's] a gigantic surprise," analysts at Denmark's Sydbank wrote in a note shortly after the announcement. "We admit that Novo Nordisk is currently facing challenges on the American market as a result of compounders' copies of Wegovy, just as the share price has fallen more than 50% [since summer 2024]," they added. "However, we also remind you that the share price has more than tripled during Lars Fruergaard Jorgensen's tenure as CEO of Novo Nordisk." NVO 5Y line Novo Nordisk. Jørgensen served at the helm of Novo Nordisk for eight years, overseeing the firm's transition from a key player in diabetes drug development to one of two market leaders in the nascent but burgeoning obesity drug space, alongside U.S. rival Eli Lilly . Novo Nordisk's share price has ridden a dramatic wave over that period, briefly rising to become Europe's most valuable company in 2023 on growing hype around weight loss drugs and their potentially wide-reaching applications . Over the past year, however, the stock's value has taken a battering on the back of rising competition from U.S. drug compounders and disappointing trial results for its next-generation obesity treatments. Shares dropped immediately on Friday's news, closing 1.8% lower, before rebounding Monday to trade up around 2.5%. Emily Field, head of European pharmaceuticals research at Barclays, told CNBC that the timing of the announcement was highly surprising. "This is all stuff that's been out there for a while. Why now? When compounding is set to go away in just a couple days. That's the part that confuses me the most," Field said in emailed comments, referring to a May 22 deadline for compounding pharmacies to cease selling copies of weight loss drugs. "This company has a reputation for, if anything, being too deliberate, too slow, too conservative — so it's just a surprising move." Deutsche Bank said it had "mixed feelings" about the news, commending Novo Nordisk for taking ownership for recent shortcomings, but also questioning the timing. "We welcome companies taking responsibility for poor performance ... even when that may not be fully under their control," the analysts wrote Friday. "Nonetheless, the decision appears a little haphazard in both timing and content," they added, noting that the news may have been better delivered during the firm's first-quarter earnings announcement earlier this month. J.P. Morgan was more sanguine on the move, however, saying it would allow the company to move its focus toward regaining market share. "While the announcement of the CEO transition is unexpected, we believe this reflects decisive action from the Novo Nordisk Foundation to put Novo in the strongest position to capitalize on the GLP-1 market opportunity over the next 10 years," the analysts wrote. What's next for Novo? The pharmaceutical industry at large has come up against increasing pressure from the Trump administration over drug pricing and prospective tariffs. Analysts told Reuters that Novo Nordisk could potentially seek an American CEO to navigate the complexities of its largest market. Novo did not immediately respond to CNBC's request for comment on the claims. However, Sydbank suggested that the decision could point to more wide-reaching issues at the firm. "The price movement in the Novo Nordisk share since the summer of 2024 has, in our estimation, also been largely driven by factors that have been beyond the influence of the Novo Nordisk management," the analysts wrote. "This raises the natural question of whether the current challenges are greater than what Novo Nordisk has expressed so far? The coming months will give a clearer answer to that," it wrote.